Redcliffe Lifetech raises $61 million in Series B


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
According to Dheeraj Jain, founder of Redcliffe Lifetech, preventative medicine aims to empower the common Indians with the information they need to take care of their health and welfare. "Redcliffe has created a one-stop diagnostic shop, offering a wide range of tests and bringing treatment closer to the client." This investment will help us scale

Redcliffe Life Sciences, located in New Delhi, announced a *$61 million funding round led by LeapFrog Investments on Friday (LeapFrog).

Other investors in the round included Healthquad, Schroders, LC Nueva, and Growth Spark Ventures, as well as current investors Chiratae Ventures and Alkemi Venture Partners.

The startup raised $10 million in its Series A fundraising round last year.

The diagnostic platform will utilize the funding to extend its low-cost but high-quality direct-to-consumer diagnostics into Tier-II, III, and IV cities, providing affordable, speedy, and accessible pathology services to millions of households.

According to Dheeraj Jain, founder of Redcliffe Lifetech, preventative medicine aims to empower the common Indians with the information they need to take care of their health and welfare. "Redcliffe has created a one-stop diagnostic shop, offering a wide range of tests and bringing treatment closer to the client." This investment will help us scale to fulfil our aim of reaching over 500 million Indians in the next five years,"

Redcliffe will also use the funds to extend its platform and expand its product offerings including radiography, illness data profiling, and lifestyle management in an attempt to reform India's healthcare focus from treatment to early diagnosis and prevention.

Across 14 cities, Redcliffe Diagnostics operates 22 state-of-the-art labs.

Its unique omnichannel infrastructure — which combines an online channel with a fleet of 400 phlebotomists operating in 100+ cities with home sample collection and an offline network of 500 collection centers — enables the company to offer over 3,500 different pathology and highly specialized tests, including genetics at affordable prices around 25-60 percent less than traditional competitors.

The company's current annualized sales run rate, according to Jain, is approximate $55- $60 million.
Redcliffe's low-cost diagnostics are intended to help reduce the burden of noncommunicable diseases (NCDs), such as heart disease, cancer, and diabetes, which harm over six million Indians each year.

Tags : #fundingalert #funding #investments #investors #redcliffe #diagnostics #indianstartups #startupfunding #healthcare #healthcarestartups #dheerajjain #smitakumar #medicircle

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026